FDA Panel Recommends Stricter Regulatory Standards For All Rapid Influenza Tests
This article was originally published in The Gray Sheet
Executive Summary
FDA’s Microbiology Devices Advisory agrees with FDA’s proposals June 13 to move rapid flu antigen tests to class II with new sensitivity and specificity thresholds and post-market standards to address concerns with poor performance.